Politicians and healthcare leaders don't agree on much about the root causes and problems with consolidation in the healthcare sector. More congressional hearings are likely to inflame the debate.
The House Judiciary Committee's Antitrust Subcommittee held a meeting last week on the state of competition among hospitals, doctors and insurance companies since the Affordable Care Act's passage. The rancorous gathering built up anticipation of a Sept. 22 Senate hearing—one in which the CEOs of Aetna, Anthem, Cigna Corp. and Humana are expected to testify.
But outside observers don't foresee congressional grandstanding influencing how the Justice Department evaluates pending deals. “What the enforcement agencies do with mergers is rarely affected by what goes in Congress,” said Lee Simowitz, a partner at Baker & Hostetler who focuses on antitrust law. “These are hearings where people are going to use them for their own purposes.”
Congress decided to examine mergers and acquisitions in the healthcare industry because of the massive deals announced this summer. Anthem is buying rival Cigna for $54 billion, while Aetna is acquiring Medicare Advantage powerhouse Humana for $37 billion.